BBK

Everbridge and Vodafone Power National Warning Day Across Germany

Retrieved on: 
Friday, September 15, 2023

The federal and state governments jointly prepare the nationwide warning day, which takes place annually, every second Thursday in September, in coordination with municipal representatives.

Key Points: 
  • The federal and state governments jointly prepare the nationwide warning day, which takes place annually, every second Thursday in September, in coordination with municipal representatives.
  • radio stations and app servers) connected to the federal government’s modular warning system (MoWaS), including the cell broadcasting system by Everbridge .
  • “We are pleased to be part of this important milestone and support Germany on the evolution of its national warning system,” said Valerie Risk, Vice President, Public Safety International at Everbridge.
  • Everbridge, in partnership with Vodafone and other MNOs, implemented Cell Broadcast technology as a complementary warning channel for the BBK in 2022.

BBK Worldwide Launches TCN® Engage, a Disruptive Tech-Service Ecosystem for an Inclusive and Positive Clinical Trial Experience

Retrieved on: 
Tuesday, February 7, 2023

BOSTON, Feb. 7, 2023 /PRNewswire/ -- BBK Worldwide (BBK), the global leader in maximizing the clinical trial experience for patients and providers, today announced the launch of TCN® Engage, a breakthrough engagement ecosystem dedicated to providing a full array of visit support services from the time a patient responds to an advertisement for a clinical trial opportunity through to their completion of the study.

Key Points: 
  • Administratively burdened and portal-fatigued, clinical trial staff have historically not had the resources necessary to devote the amount of time needed to effectively enroll patients.
  • "Everything key stakeholders understand about creating an informed participant and managing their experience is now accessible from one platform," says Joan F. Bachenheimer, Founder, Chief Executive Officer, BBK Worldwide.
  • TCN Engage harnesses intelligence from BBK's 40-year history of service to healthcare systems, hospitals, providers and the research and development community.
  • TCN Engage is helping sponsors to create meaningful connections within the entire study community and, most importantly, offer patients a more accessible, inclusive and equitable experience.

BBK Worldwide's Clinical Cuisine™ Named One of the Most Innovative Products of the Year by PM360 Magazine

Retrieved on: 
Wednesday, January 11, 2023

BOSTON, Jan. 11, 2023 /PRNewswire/ -- BBK Worldwide (BBK), a full-service R&D marketing firm and a global leader in clinical trial experience, today announced that its clinical trial meal preparation and delivery service Clinical Cuisine™ was named one of the most innovative products of 2022 by leading industry publication PM360.

Key Points: 
  • BOSTON, Jan. 11, 2023 /PRNewswire/ -- BBK Worldwide (BBK), a full-service R&D marketing firm and a global leader in clinical trial experience, today announced that its clinical trial meal preparation and delivery service Clinical Cuisine™ was named one of the most innovative products of 2022 by leading industry publication PM360.
  • Clinical Cuisine is a first-of-its-kind meal preparation and delivery service for clinical trial participants and their caregivers.
  • It is designed to help patients and caregivers stay engaged and supported during clinical trial participation by removing the burden of meal planning and preparation.
  • The editorial staff of PM360 evaluated each submission and selected their picks for the most innovative, regardless of category.

Patient Recruitment and Retention Services Market worth $5.45 billion by 2030 - Exclusive Report by InsightAce Analytic

Retrieved on: 
Wednesday, July 20, 2022

According to the latest research by InsightAce Analytic, the global patient recruitment and retention services market is valued at US$ 3.63 billion in 2021, and it is expected to reach US$ 5.45 billion by 2030, with a CAGR of 4.7% during the forecast period of 2022-2030.

Key Points: 
  • According to the latest research by InsightAce Analytic, the global patient recruitment and retention services market is valued at US$ 3.63 billion in 2021, and it is expected to reach US$ 5.45 billion by 2030, with a CAGR of 4.7% during the forecast period of 2022-2030.
  • Patient recruiting is seen as one of the rate-limiting phases when it comes to getting medicines to market, among other well-known difficulties.
  • The growth of the North American clinical trial patient recruitment services market has been attributed to the presence of significant CROs providing support services like patient recruitment and multinational pharmaceutical & biopharmaceutical companies making significant investments in clinical research.
  • Global Patient Recruitment and Retention Services Market, by Therapeutic Areas, 2022-2030 (Value US$ Bn)

Patient Recruitment and Retention Services Market worth $5.45 billion by 2030 - Exclusive Report by InsightAce Analytic

Retrieved on: 
Wednesday, July 20, 2022

According to the latest research by InsightAce Analytic, the global patient recruitment and retention services market is valued at US$ 3.63 billion in 2021, and it is expected to reach US$ 5.45 billion by 2030, with a CAGR of 4.7% during the forecast period of 2022-2030.

Key Points: 
  • According to the latest research by InsightAce Analytic, the global patient recruitment and retention services market is valued at US$ 3.63 billion in 2021, and it is expected to reach US$ 5.45 billion by 2030, with a CAGR of 4.7% during the forecast period of 2022-2030.
  • Patient recruiting is seen as one of the rate-limiting phases when it comes to getting medicines to market, among other well-known difficulties.
  • The growth of the North American clinical trial patient recruitment services market has been attributed to the presence of significant CROs providing support services like patient recruitment and multinational pharmaceutical & biopharmaceutical companies making significant investments in clinical research.
  • Global Patient Recruitment and Retention Services Market, by Therapeutic Areas, 2022-2030 (Value US$ Bn)

PUBLICIS HEALTH ACQUIRES BBK WORLDWIDE

Retrieved on: 
Tuesday, January 18, 2022

NEW YORK, Jan. 18, 2022 /PRNewswire/ -- Publicis Health, the health and wellness vertical of Publicis Groupe, today announced the acquisition of BBK Worldwide (BBK), a full-service R&D marketing firm and a global leader in clinical trial experience (CTE).BBK enables biotech and pharmaceutical customers to accelerate R&D programs, driving research forward through the unique integration of patient-centric services and proprietary technology, complementing Publicis Health's existing CTE capabilities.

Key Points: 
  • NEW YORK, Jan. 18, 2022 /PRNewswire/ -- Publicis Health, the health and wellness vertical of Publicis Groupe, today announced the acquisition of BBK Worldwide (BBK), a full-service R&D marketing firm and a global leader in clinical trial experience (CTE).BBK enables biotech and pharmaceutical customers to accelerate R&D programs, driving research forward through the unique integration of patient-centric services and proprietary technology, complementing Publicis Health's existing CTE capabilities.
  • As part of the acquisition, Publicis Health will acquire BBK Holdings, which in addition to BBK Worldwide, is the parent company of creative advertising agency 320Agency, technology company TCN Technologies, and solution center RSG Engagement Solution Center.
  • At Publicis Health, we are united around one purpose: to create a world where people are equipped and motivated to take control of their health.
  • Publicis Health companies include: BBK Worldwide, Digitas Health, Heartbeat, insync, Langland, Payer Sciences, PlowShare Group, Publicis Health France, Publicis Health Media, Razorfish Health, Saatchi & Saatchi Wellness, and Verilogue.

Cellectar Reports Financial Results for the Third Quarter 2021 and Provides a Corporate Update

Retrieved on: 
Monday, November 8, 2021

FLORHAM PARK, N.J., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc.(NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of targeted drugs for the treatment of cancer, today announced financial results for the third quarter ended September 30, 2021 and provided a corporate update.

Key Points: 
  • FLORHAM PARK, N.J., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc.(NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of targeted drugs for the treatment of cancer, today announced financial results for the third quarter ended September 30, 2021 and provided a corporate update.
  • The grant will support the ongoing global pivotal study and clinical development of iopofosine in Waldenstroms macroglobulinemia (WM).
  • These services are designed to improve patients and their caregiver's access to high quality care and innovative treatments for their cancer.
  • These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update any such forward-looking statements.

Cellectar Announces Innovative Concierge Service for Patients Participating in Its Clinical Studies

Retrieved on: 
Monday, October 25, 2021

These services are designed to improve patients and their caregiver's access to high quality care and innovative treatments for their cancer.

Key Points: 
  • These services are designed to improve patients and their caregiver's access to high quality care and innovative treatments for their cancer.
  • Cellectars new concierge services program underscores our focus on patients and our commitment to providing them with best-in-class treatments and support.
  • We recognize the challenges facing patients and their families as they battle cancer and navigate the clinical study process and are honored to support them through this journey.
  • Their tools inspire study communities and alleviate site administrative burdens, enabling doctors and nurses to spend more time with patients.

Candid acquires media agency De Media Maatschap

Retrieved on: 
Thursday, October 14, 2021

AMSTERDAM, Oct. 14, 2021 /PRNewswire/ -- Candid announces today that De Media Maatschap is joining the Candid platform.

Key Points: 
  • AMSTERDAM, Oct. 14, 2021 /PRNewswire/ -- Candid announces today that De Media Maatschap is joining the Candid platform.
  • STROOM part of Candid since 2017 and De Media Maatschap will merge into a new media agency, with offices in Amsterdam and Rotterdam.
  • Samantha Catsburg (STROOM) and Willem-Jan Nouwens and Michael Gottmer (both De Media Maatschap) will jointly manage the new agency.
  • Samantha Catsburg (agency lead STROOM): "STROOM and De Media Maatschap have many similarities; the working practice and culture of the two agencies are closely related.

Candid acquires media agency De Media Maatschap

Retrieved on: 
Thursday, October 14, 2021

AMSTERDAM, Oct. 14, 2021 /PRNewswire/ -- Candid announces today that De Media Maatschap is joining the Candid platform. STROOM – part of Candid since 2017 – and De Media Maatschap will merge into a new media agency, with offices in Amsterdam and Rotterdam. Samantha Catsburg (STROOM) and Willem-Jan Nouwens and Michael Gottmer (both De Media Maatschap) will jointly manage the new agency.

Key Points: 
  • AMSTERDAM, Oct. 14, 2021 /PRNewswire/ -- Candid announces today that De Media Maatschap is joining the Candid platform.
  • STROOM part of Candid since 2017 and De Media Maatschap will merge into a new media agency, with offices in Amsterdam and Rotterdam.
  • Samantha Catsburg (STROOM) and Willem-Jan Nouwens and Michael Gottmer (both De Media Maatschap) will jointly manage the new agency.
  • Samantha Catsburg (agency lead STROOM): "STROOM and De Media Maatschap have many similarities; the working practice and culture of the two agencies are closely related.